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Abstract
Objectives. Anti-TNF therapy has significantly improved outcomes for patients with severe RA. In the UK,
changing financial restrictions and increasing experience with their use may have resulted in changes to
the way physicians use anti-TNF therapies. The aim of this analysis was to examine changes in disease
characteristics and response rates among patients starting anti-TNF therapy for RA over an 8-year period.
Methods. A total of 11216 RA patients registered between 2001 and 2008 with the British Society for
Rheumatology Biologics Register were included and stratified according to year of first anti-TNF prescrip-
tion. Baseline characteristics and treatment response were compared year on year using logistic and
linear regression models.
Results. Mean RA disease activity and severity of new anti-TNF-treated patients decreased between 2001
and 2008. The mean disease duration remained high (11 years in 2008) although the proportion of patients
having disease duration <5 years increased significantly (2001: 9%; 2008: 29%; P<0.001). The majority of
patients had failed three DMARDs on average before the first anti-TNF prescription. There was an increase
in both the proportion of EULAR good responders at 1 year (2001: 18%; 2008: 30%; P<0.001) and in the
number of patients achieving remission (2001: 8%; 2008: 17%; P<0.001). Drug survival remained
relatively stable over the study years.
Conclusions. There is a significant trend towards earlier use of anti-TNF therapies in patients with less
severe disease, although the mean disease duration at first treatment remains high. This has correlated
with improvements in outcome. These results support the earlier use of anti-TNF therapies in RA.
Key words: Rheumatoid arthritis, Anti-TNF therapy, Prescription pattern, Treatment response,
Treatment outcome, Remission.
Introduction
The anti-TNF agents have significantly improved out-
comes for patients with severe RA. Since their licence in
the late 1990s, the utility and place of anti-TNF therapies in
the treatment of RA has been expanding, with increasing
data to support their earlier use [1–4]. Further data has also
supported the benefits of combining these agents with
MTX and other DMARDS, both in those naı ¨ve to DMARD
treatment [4, 5] and in those resistant to MTX [6].
There are some data to suggest that these published
observations are translating into clinical practice. A
number of studies outside of the UK have demonstrated
that the prescription of anti-TNF therapies in both early
and established RA is increasing [7–11]. A US study by
Yazici et al. [9] also demonstrated that co-prescription
with MTX increased over the period from 1999 to 2005.
However, whether these changes in use have translated
into better outcomes in routine clinical practice is less
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester Academic Health Sciences Centre, Manchester, UK.
Correspondence to: Kimme Hyrich, Arthritis Research UK
Epidemiology Unit, Stopford Building, University of Manchester,
Manchester Academic Health Sciences Centre, Oxford Road,
Manchester M13 9PT, UK. E-mail: kimme.hyrich@manchester.ac.uk
Submitted 25 March 2010; revised version accepted 8 June 2010.
! The Author(s) 2010. Published by Oxford University Press on behalf of The British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
RHEUMATOLOGY
Rheumatology 2011;50:117–123
doi:10.1093/rheumatology/keq209
Advance Access publication 29 July 2010
C
L
I
N
I
C
A
L
S
C
I
E
N
C
Eclear. Analysis of the Danish Biologics Registry (DANBIO)
data set found that baseline DASs decreased over a
5-year period [12]. The 12-month EULAR and DAS-28 re-
sponses over the same period of observation also signifi-
cantly improved. However, data on whether anti-TNF
therapies were being used earlier in disease over this
same period were not presented. The aim of this study
was to explore the secular patterns of anti-TNF prescrib-
ing in the UK over an 8-year period (2001–08) including
changes in the baseline characteristics of the patients and
the association with treatment response, improvements in
disability and treatment survival.
Patients and methods
Patients included this study were participants in the
British Society for Rheumatology Biologics Register
(BSRBR) [13]. The BSRBR aimed to recruit 4000 patients
with RA starting each of the three currently available
(2009) anti-TNF therapies: etanercept, infliximab and ada-
limumab. Recruitment to the etanercept and infliximab
cohort began in October 2001 and adalimumab recruit-
ment began in 2003. The target of 4000 patients was
reached for etanercept in May 2005, infliximab in 2007
and adalimumab at the end of 2008. The prescription of
anti-TNF therapy in the UK is according to the national
guidelines [14] and in England and Wales, governed by
the National Institute of Clinical Excellence (NICE) [15].
Since their approval in the UK, these treatments have
been reserved for patients with a 28-joint count DAS-28
[16] >5.1 despite treatment with at least two standard
DMARDs (one of which must include MTX).
At treatment start, details including diagnosis, disease
activity, new biologic therapy, past and current anti-
rheumatictherapiesandinformationonothercomorbidities
were collected fromthe treating physician. Thepatient also
completed an HAQ adapted for British use [17]. Follow-up
is completed at 6-month intervals for the first 3 years and
annually thereafter. At each follow-up, the physician com-
pletes a questionnaire detailing any changes in
anti-rheumatic therapy, including dates and reasons for
any changes and current disease activity. For the first 3
years of the study, an HAQ form is mailed every 6 months
to the patients’ homes to complete and return. Response
rates have been very good, with >90% of all hospital
follow-up forms returned and 75% of patient question-
naires returned. The study received ethical approval from
the North West UK Research Ethics Committee (MREC 00/
8/53) and all patients provided written informed consent.
This analysis was limited to biologic-naı ¨ve patients
starting their first anti-TNF within 6 months of registration
with the BSRBR. Patients were divided into cohorts based
on the calendar year of treatment start (2001–08). All
anti-TNF therapies were analysed together. Differences
in baseline characteristics across the years were com-
pared using linear and logistic regression models, with
the characteristic as the outcome and year as a covariate.
Improvements in disease activity and disability were
compared in three ways. First, the absolute mean
change in DAS-28 and HAQ score were compared
across the study years using linear regression models.
Secondly, the proportion of EULAR responders [18] (mod-
erate and good responders vs non-responders) and the
proportion of patients in DAS-28 remission [19] (defined as
DAS-28<2.6) were compared using a logistic regression
model. Finally, the proportions of patients with a EULAR
non-response, moderate response or good response in
each year were compared using an ordinal logistic regres-
sion model, which models the odds of being in a higher
response category for each consecutive calendar year.
Anti-TNF survival at 1 and 2 years was examined for
each consecutive treatment year using Kaplan–Meier sur-
vival curves and compared across the years using Cox
proportional hazards models. All outcome analyses were
adjusted additionally for choice of anti-TNF agent.
Results
Until 30 June 2009, 11216 patients with RA starting their
first anti-TNF therapy within 6 months of study registration
had been recruited to the BSRBR from 257 hospitals
across the UK (3940 etanercept, 3316 infliximab and
3960 adalimumab). The proportion of patients starting
each of the three drugs differed over the course of the
study relating to changes in recruiting patterns within the
BSRBR (Table 1).
Between 2001 and 2008, there was a significant
trend towards the use of these drugs in patients who
were older and with shorter disease duration (Table 1).
Only 13% of the cohort recruited in 2002 had disease
duration <5 years. This increased to 29% in 2008.
However, in 2008, the overall mean disease duration
was still high at 11 years, with only 5% of patients receiv-
ing their first biologic within 2 years of disease onset.
Despite NICE guidance allowing the use of anti-TNF
after two failed DMARDs (including MTX), the mean
number of failed DMARDs before starting anti-TNF re-
mained at three in 2008, with only 30% of patients receiv-
ing their anti-TNF after only two failed DMARDs. The
proportion of patients with at least one comorbid condi-
tion remained constant at 60% across the years.
The use of concurrent DMARDs remained unchanged
over the study period in patients starting infliximab, with
85% of patients receiving MTX (Table 2). The proportion
of patients receiving concurrent DMARDs with either eta-
nercept or adalimumab increased with 44% of patients
starting etanercept in combination with MTX in 2005 and
62% starting adalimumab in combination with MTX in
2008. This compared with only 21% of patients starting
etanercept in 2002 and 37% of patients starting adalimu-
mab in 2003. The proportion of patients receiving oral
corticosteroids decreased over the study years.
The DAS-28 was available for 11119 (99%) patients
at baseline, 10291 (92%) patients at 6 months and 8646
(77%) patients at 1 year. HAQ scores were available for
10 672 (95%) patients at baseline, 8155 (72%) patients at
6 months and 7546 (67%) of patients at 1 year. The mean
baseline DAS-28 decreased over the study years, al-
though remained very high, in keeping with UK guidelines
[mean DAS-28 6.38 (0.98) in 2008] (Table 3). The baseline
118 www.rheumatology.oxfordjournals.org
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Kimme L. Hyrich et al.HAQ score decreased from 2.21 (S.D. 0.57) in 2001 to 1.87
(S.D. 0.65) in 2008. Although there was a trend towards a
greater improvement in both HAQ and DAS-28 scores
over the study years, particularly at 12 months, this did
not reach statistical significance. Despite this there was a
significant improvement year on year in the proportion of
patients classified as responders (moderate or good),
good responders and in DAS-28 remission. There was a
minimal trend towards improved drug survival at both 1
and 2 years, with the lowest drug survival observed
among those patients initiating treatment in 2002.
Discussion
The results of this large study demonstrate that, even
within the restrictions of the UK health-care system,
anti-TNF agents are being used earlier in patients with
lesser disease activity and disability, and more often in
combination with DMARDS. These observations have
been associated with significant increases in treatment
response, particularly in the rates of EULAR good
response and DAS remission.
We also observed that anti-TNF agents are being used
increasingly in older patients. This observation may reflect
an increasing comfort of anti-TNF use among prescribing
clinicians as data on the use in older patients increases
[20, 21]. However, the proportion of patients with comor-
bid conditions has not significantly changed over the
course of the study, suggesting there is likely to be a
selection bias towards the use of anti-TNF in healthier
patients since comorbidity generally is more common
in older RA patients.
It is interesting that although the proportion of patients
with disease duration <5 years has increased over the
study period, the proportion of patients with very early dis-
ease (<2 years) remained low (5% in 2008) and the mean
disease duration remained high at 11 years, suggesting
that there remains a large proportion of patients who are
not receiving anti-TNF therapy until late into their disease.
National guidelines state that patients can receive an
anti-TNF therapy if they have a DAS-28>5.1 despite a
trial of at least two DMARDs, including MTX, for a period
of 6 months each [14]. Presumably, those patients who
received anti-TNF therapy early in the study were those
patients with the longest disease duration who had been
‘waiting’ for further effective treatment, thus the high
observed number of previous failed DMARDs in the earlier
years of the study. However, in 2008, only 30% of patients
had tried only two DMARDs before receiving anti-TNF.
Why disease duration and the number of DMARDs tried
before anti-TNF therapy should not have decreased further
over the course of the study is not clear. We did not cap-
ture the reasons patients had failed previous DMARDs
(e.g. primary inefficacy, secondary inefficacy and adverse
events), which could effect the length of time a patient
spends on each DMARD. It was also not always clear
whether some past DMARDs had actually been received
in combination, thus increasing this number. However, it is
possible that the responses seen in this study could be
improved even further through the earlier introduction of
anti-TNF, with a greater proportion of patients receiving
these therapies after failing only two DMARDs.
Despite the improvements in disease activity, we did
not observe a substantial increase in drug survival. A simi-
lar pattern has been observed in other cohorts [9, 12].
Increasing alternative treatment options may, in part, be
responsible for this finding, with inadequate responders
switching to an alternative anti-TNF or other classes of
biologics sooner in the treatment course balanced by
good responders remaining on treatment longer. A study
of the US PharMetrics claims database found that, be-
tween 2000 and 2005, patients were increasingly more
likely to switch between anti-TNF agents with a shorter
duration of treatment before the change over the years
of the study [9]. It is also interesting to note the particularly
low 2-year drug survival among patients starting anti-TNF
therapy in 2002. This is likely explained in part by the
temporary worldwide shortage of etanercept [22], with
patients subsequently switching anti-TNF agents for
reasons of patient choice rather than non-response or
adverse events.
One potential limitation of the study was the restric-
tion of recruitment to the BSRBR of 4000 biologic-naı ¨ve
patients starting each of the three available anti-TNF
agents. This sample size was chosen based on the
power to detect a doubling in lymphoma risk among
anti-TNF users. As recruitment of patients receiving
etanercept was completed in 2005, the results of
this study cannot be used to comment on the patterns
of specific anti-TNF use in the UK. However, up until
2005, when the study was actively recruiting all three
anti-TNF therapies, it was estimated that 7% of all RA
patients in the UK were receiving anti-TNF therapies [23]
and that the register was capturing 80% of these pa-
tients. There is no reason to believe that the trend towards
earlier prescribing of infliximab and adalimumab would
not also be true for patients starting etanercept since
2005.
A further limitation may be the external validity of our
results to other health-care systems, which may place dif-
ferent restrictions on the use of anti-TNF therapies. In turn,
when comparing registry data from different countries, the
differences in prescribing guidelines should be con-
sidered. The use of anti-TNF therapy in RA patients in
the USA is estimated to be much higher. In the
Consortim of Rheumatology Researchers of North
America database, 40% of patients with established RA
(disease >3 years) and 25% of those with early RA (dis-
ease <3 years) had received treatment with anti-TNF [11].
The baseline level of disease also differs from other coun-
tries [in 2005, 38% of patients registered in DANBIO
(Denmark) had moderate disease activity (baseline
DAS-28 between 3.2 and 5.1)]. Whether responses to
anti-TNF are higher in these countries is less clear, al-
though good EULAR response rates were estimated to
be as high as 50% in Denmark in 2005 [12]. However,
even within our very severe patients, we have seen a
significant trend towards better outcomes over the
past 8 years.
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Anti-TNF therapy for RAIn conclusion, this study has shown that in the UK,
anti-TNF agents are being used earlier in disease and in-
creasingly in combination with DMARDs. These changes
have been associated with marked improvements in treat-
ment outcome.
Rheumatology key messages
. Patients with RA are receiving anti-TNF therapies
earlier in disease.
. Many patients still receive their first anti-TNF drug
after the first 5 years of disease.
. Response scores and remission rates have im-
proved significantly since the earliest use of
anti-TNF therapy.
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